Emplicure communicates the outcome of the exercise of warrants of series TO1 and the Company receives app. SEK 12.3 million
Emplicure AB (publ) ("Emplicure" or the "Company") announces the outcome of the exercise of warrants of series TO1, which were issued during the second quarter of 2021. A total of 5,902,512 warrants of series TO1 were exercised, corresponding to approximately 61.5 percent of outstanding warrants of series TO1, for subscription of 5,902,512 shares at a subscription price of SEK 2.09 per share. Through the exercise of the warrants of series TO1, Emplicure receives approximately SEK 12.3 million before issue costs.
The subscription period for the exercise of the warrants of series TO1 took place during the period from April 29, 2022 up to and including May 13, 2022.
Exercised warrants have been replaced with interim shares (IA) pending registration of the shares with the Swedish Companies Registration Office. The conversion of interim shares into shares is expected to take place within three (3) weeks.
Number of shares, share capital and dilution Through the exercise of warrants of series TO1, the number of shares in Emplicure increases by 5,902,512, from 20,558,000 shares to 26,460,512shares. The share capital increases with SEK 295,125.600, from SEK 1,027,900 to SEK 1,323,025.600.
For existing shareholders who did not exercise any warrants of series TO1, the dilution amounts to approximately 22.3 percent, based on the number of shares in the Company after the exercise of the warrants.
Advisors Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.
This information is such that Emplicure AB (publ) is required to make public in accordance with the EUs Market Abuse Regulation (MAR). The information was made public by the Companys contact persons below on May 17, 2022 at 08:20 CET.
For more information, please contact:
Torbjörn W. Larsson CEO Phone: +46 (0)70 747 65 99 Email: firstname.lastname@example.org
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white tobacco-free nicotine pouches as the first product. Read more at www.emplicure.com